MORRISTOWN, N.J., Oct. 15 /PRNewswire-FirstCall/ — Watson
Pharmaceuticals, Inc. (NYSE:
WPI), today announced that its subsidiary, Watson Laboratories,
Inc., has received approval from the United States Food and Drug
Administration on its Abbreviated New Drug Application (ANDA) for
Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and
5/10mg capsules, the generic equivalent to Novartis’ Lotrel®
capsules. The ANDA was acquired as part of Watson’s acquisition of
the Arrow Group. Watson intends to begin shipping the product
immediately.
Lotrel ® capsules and its generic equivalents had total U.S.
sales of approximately $1.05 Billion for the twelve months ending
June 30, 2010, according to IMS Health. Amlodipine
Besylate/Benazepril capsules are indicated to prevent and treat
high blood pressure.
About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals,
Inc. is a leading global specialty pharmaceutical company.
The Company is engaged in the development and distribution of
generic pharmaceuticals and specialized branded pharmaceutical
products focused on Urology and Women’s Health. Watson has
operations in many of the world’s established and growing
international markets.
For press release and other company information, visit Watson
Pharmaceuticals’ Web site at http://www.watson.com.
Forward-Looking Statement Statements contained in this press
release that refer to non-historical facts are forward-looking
statements that reflect Watson’s current perspective of existing
information as of the date of this release. It is important
to note that Watson’s goals and expectations are not predictions of
actual performance. Actual results may differ materially from
Watson’s current expectations depending upon a number of factors,
risks and uncertainties affecting Watson’s business
‘/>”/>
